oncology

Former Shire execs set up shop to take a shot at 'under the radar' cancer target
Former Shire execs set up shop to take a shot at 'under the radar' cancer target
Endpoints
cancer
oncology
Shire
OncoOne
Flag link:
New Meds Set to Reshape US CNS and oncology Markets
New Meds Set to Reshape US CNS and oncology Markets
Xconomy
CNS
oncology
cancer
Clarivate Analytics
Biohaven
rimegepant
Novartis
OMB-157
Flag link:
AstraZeneca cans cancer pipeline efforts
AstraZeneca cans cancer pipeline efforts
Fierce Biotech
AstraZeneca
earnings
R&D
cancer
oncology
Flag link:
Biopharma’s big bet on cancer is laid bare
Biopharma’s big bet on cancer is laid bare
EP Vantage
cancer
oncology
M&A
licensing
Flag link:
Evolutionary History of 2,658 Cancers Shows Promise for Early Detection
Evolutionary History of 2,658 Cancers Shows Promise for Early Detection
BioSpace
cancer
oncology
genomes
diagnostics
genome sequencing
Flag link:
Sales rep tips for oncologist calls: Keep it short, use visuals and bring new info, says consultancy
Sales rep tips for oncologist calls: Keep it short, use visuals and bring new info, says consultancy
Fierce Pharma
drug reps
pharma reps
oncologists
physicians
ZoomRx
oncology
sales calls
Flag link:
RAPT Therapeutics Files for $100 Million Offering
RAPT Therapeutics Files for $100 Million Offering
CP WIre
RAPT Therapeutics
oncology
Flag link:
Nearly half of doctors did not discuss trials with cancer patients – survey
Nearly half of doctors did not discuss trials with cancer patients – survey
Pharmaforum
cancer
oncology
clinical trials
Flag link:
Oncology biotech Revolution Medicines sets terms for $150 million IPO
Oncology biotech Revolution Medicines sets terms for $150 million IPO
NASDAQ
Revolution Medicines
IPOs
oncology
RAS pathway
Flag link:
A Cure for Cancer Might Be on the Way -- and It Could Turn Healthcare Investing Upside Down
A Cure for Cancer Might Be on the Way -- and It Could Turn Healthcare Investing Upside Down
Motley Fool
cancer
oncology
R&D
Flag link:
Eli Lilly cuts three cancer drugs amid Q4 clear-out
Eli Lilly cuts three cancer drugs amid Q4 clear-out
Fierce Biotech
Eli Lilly
galunisertib
drug development
oncology
cancer
Flag link:
Almost 50 Non-Oncology Drugs Found to Kill Cancer Cells
Almost 50 Non-Oncology Drugs Found to Kill Cancer Cells
BioSpace
Broad Institute
Harvard
cancer
oncology
drug repurposing
Flag link:
What Does the Future Hold for Nextcure?
What Does the Future Hold for Nextcure?
Motley Fool
NextCure
Eli Lilly
oncology
Flag link:
JPM: Biotech, VC execs on where the industry should look beyond cancer
JPM: Biotech, VC execs on where the industry should look beyond cancer
Fierce Biotech
oncology
cancer
Alzheimer's disease
diabetes
venture capital
JPMHC 2020
Flag link:
Fostering Oncology Product Development for Kids with Cancer
Fostering Oncology Product Development for Kids with Cancer
FDA Law Blog
pediatric
oncology
FDA
drug development
Flag link:
Drug developers take fresh aim at 'guided-missile' cancer drugs
Drug developers take fresh aim at 'guided-missile' cancer drugs
Reuters
cancer
oncology
drug development
antibody-drug conjugate
Flag link:
The first biotech IPO of the new decade has landed — and of course it's another cancer drug developer
The first biotech IPO of the new decade has landed — and of course it's another cancer drug developer
Endpoints
Black Diamond Therapeutics
IPOs
oncology
cancer
I-Mab Biopharma
Flag link:
Amgen to Sell Cancer Drugs in China Thanks to $2.7B Deal with BeiGene
Amgen to Sell Cancer Drugs in China Thanks to $2.7B Deal with BeiGene
Xtalks
Amgen
BeiGene
oncology
China
Flag link:
Drugmakers rebranding around oncology, rare diseases could provide 2020 preview
Drugmakers rebranding around oncology, rare diseases could provide 2020 preview
Fierce Pharma
oncology
Rare Diseases
AstraZeneca
GSK
Alexion
Takeda
Soliris
Flag link:
Takeda Strikes Potential $1 Billion Oncology Deal with Turnstone
Takeda Strikes Potential $1 Billion Oncology Deal with Turnstone
BioSpace
Takeda
Turnstone Biologics
RIVAL-01
cancer
oncology
Flag link:

Pages